Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 43, 2011, Pages

  Shimano, Masayuki ^a   Ouchi, Noriyuki ^a   Nakamura, Kazuto ^a   Van Wijk, Bram ^b   Ohashi, Koji ^a   Asaumi, Yasuhide ^a   Higuchi, Akiko ^a   Pimentel, David R ^a   Sam, Flora ^a   Murohara, Toyoaki ^c   Van Den Hoff, Maurice J B ^b   Walsh, Kenneth ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; TSC 36

Indexed keywords

FOLLISTATIN; FOLLISTATIN LIKE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PHENYLEPHRINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HEART DEVELOPMENT; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART VENTRICLE PERFORMANCE; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; KNOCKOUT MOUSE; MOUSE; NEWBORN; NONHUMAN; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CARDIOMEGALY; DNA PRIMERS; ECHOCARDIOGRAPHY; FOLLISTATIN-RELATED PROTEINS; MICE; MICE, KNOCKOUT; MYOCYTES, CARDIAC; PRESSURE; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; VENTRICULAR REMODELING;

MUS;

EID: 80055086667     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1108559108     Document Type: Article

References (50)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561-1566. (Pubitemid 20176696)
2. Molkentin JD, Dorn GW, 2nd (2001) Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 63:391-426. (Pubitemid 32304323)
3. Frey N, Katus HA, Olson EN, Hill JA (2004) Hypertrophy of the heart: A new therapeutic target? Circulation 109:1580-1589. (Pubitemid 38451712)
4. Frost RJ, Engelhardt S (2007) A secretion trap screen in yeast identifies protease inhibitor 16 as a novel antihypertrophic protein secreted from the heart. Circulation 116:1768-1775. (Pubitemid 350287101)
5. Doroudgar S, Glembotski CC (2011) The cardiokine story unfolds: Ischemic stressinduced protein secretion in the heart. Trends Mol Med 17:207-214.
6. Heineke J, et al. (2010) Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 121:419-425.
7. Oshima Y, et al. (2009) Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury. Circulation 120:1606-1615.
8. Shibata R, et al. (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10:1384-1389. (Pubitemid 40022722)
9. Shiojima I, et al. (2005) Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115:2108-2118. (Pubitemid 41134152)
10. Xu J, et al. (2006) GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98:342-350.
11. Oshima Y, et al. (2008) Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation 117:3099-3108.
12. Lara-Pezzi E, et al. (2008) Expression of follistatin-related genes is altered in heart failure. Endocrinology 149:5822-5827.
13. Mashimo J, Maniwa R, Sugino H, Nose K (1997) Decrease in the expression of a novel TGF beta1-inducible and ras-recision gene, TSC-36, in human cancer cells. Cancer Lett 113:213-219. (Pubitemid 27113251)
14. Shibanuma M, Mashimo J, Mita A, Kuroki T, Nose K (1993) Cloning from a mouse osteoblastic cell line of a set of transforming-growth-factor-beta 1-regulated genes, one of which seems to encode a follistatin-related polypeptide. Eur J Biochem 217:13-19. (Pubitemid 23305265)
15. Ouchi N, et al. (2010) DIP2A functions as a FSTL1 receptor. J Biol Chem 285:7127-7134.
16. Tanaka M, et al. (2010) DIP2 disco-interacting protein 2 homolog A (Drosophila) is a candidate receptor for follistatin-related protein/follistatin-like 1 - analysis of their binding with TGF-β superfamily proteins. FEBS J 277:4278-4289.
17. Chan QK, et al. (2009) Tumor suppressor effect of follistatin-like 1 in ovarian and endometrial carcinogenesis: A differential expression and functional analysis. Carcinogenesis 30:114-121.
18. Clutter SD, Wilson DC, Marinov AD, Hirsch R (2009) Follistatin-like protein 1 promotes arthritis by up-regulating IFN-gamma. J Immunol 182:234-239.
19. Kawabata D, et al. (2004) Ameliorative effects of follistatin-related protein/TSC-36/FSTL1 on joint inflammation in a mouse model of arthritis. Arthritis Rheum 50:660-668. (Pubitemid 38198850)
20. Miyamae T, et al. (2006) Follistatin-like protein-1 is a novel proinflammatory molecule. J Immunol 177:4758-4762. (Pubitemid 44469810)
21. Schiekofer S, et al. (2006) Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure. Physiol Genomics 27:156-170. (Pubitemid 46702029)
22. Widera C, et al. (2009) Circulating concentrations of follistatin-like 1 in healthy individuals and patients with acute coronary syndrome as assessed by an immunoluminometric sandwich assay. Clin Chem 55:1794-1800.
23. El-Armouche A, et al. (2011) Follistatin-like 1 in chronic systolic heart failure: A marker of left ventricular remodeling. Circ Heart Fail 4(5):621-627.
24. Ikeda Y, et al. (2009) Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. J Biol Chem 284:35839-35849.
25. Zhang P, et al. (2008) AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 52:918-924.
26. Arai KY, Tsuchida K, Uehara K, Taya K, Sugino H (2003) Characterization of rat follistatin-related gene: Effects of estrous cycle stage and pregnancy on its messenger RNA expression in rat reproductive tissues. Biol Reprod 68:199-206. (Pubitemid 36076337)
27. van den Berg G, Somi S, Buffing AA, Moorman AF, van den Hoff MJ (2007) Patterns of expression of the Follistatin and Follistatin-like1 genes during chicken heart development: A potential role in valvulogenesis and late heart muscle cell formation. Anat Rec (Hoboken) 290:783-787.
28. Adams D, Larman B, Oxburgh L (2007) Developmental expression of mouse Follistatin-like 1 (Fstl1): Dynamic regulation during organogenesis of the kidney and lung. Gene Expr Patterns 7:491-500. (Pubitemid 46172930)
29. Shimano M, et al. (2011) Cardiac myocyte-specific ablation of follistatin-like 3 attenuates stress-induced myocardial hypertrophy. J Biol Chem 286:9840-9848.
30. Geng Y, et al. (2011) Follistatin-like 1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling antagonist in controlling mouse lung development. Proc Natl Acad Sci USA 108:7058-7063.
31. Ouchi N, et al. (2008) Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitricoxide synthase-dependent mechanism. J Biol Chem 283:32802-32811.
32. Shimano M, et al. (2010) Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J Mol Cell Cardiol 49:210-220.
33. Lee SJ (2007) Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS ONE 2:e789.
34. Ouchi N, et al. (2004) Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 279:1304-1309. (Pubitemid 38082655)
35. Kempf T, Wollert KC (2004) Nitric oxide and the enigma of cardiac hypertrophy. Bioessays 26:608-615. (Pubitemid 38758338)
36. Murohara T, et al. (1998) Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101:2567-2578. (Pubitemid 28270451)
37. Ouchi N, Shibata R, Walsh K (2005) AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circ Res 96:838-846. (Pubitemid 40604967)
38. Izumiya Y, et al. (2006) Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 47:887-893. (Pubitemid 44297560)
39. Tian R, Musi N, D'Agostino J, Hirshman MF, Goodyear LJ (2001) Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 104:1664-1669. (Pubitemid 32947531)
40. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR (2004) Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 279:32771-32779. (Pubitemid 39014736)
41. Chan AY, et al. (2008) Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem 283:24194-24201.
42. Miller EJ, et al. (2008) Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 451:578-582. (Pubitemid 351186266)
43. Li D, et al. (2011) Follistatin-like protein 1 is elevated in systemic autoimmune diseases and correlated with disease activity in patients with rheumatoid arthritis. Arthritis Res Ther 13(1):R17.
44. Wilson DC, et al. (2010) Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 62:2510-2516.
45. Le Luduec JB, et al. (2008) An immunomodulatory role for follistatin-like 1 in heart allograft transplantation. Am J Transplant 8:2297-2306.
46. Frangogiannis NG (2004) Chemokines in the ischemic myocardium: From inflammation to fibrosis. Inflamm Res 53:585-595.
47. Silva M, et al. (2011) The BMP antagonist follistatin-like 1 is required for skeletal and lung organogenesis. PLoS One 6(8):e22616.
48. Agah R, et al. (1997) Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. J Clin Invest 100:169-179. (Pubitemid 27311255)
49. Sternberg EA, et al. (1988) Identification of upstream and intragenic regulatory elements that confer cell-type-restricted and differentiation- specific expression on the muscle creatine kinase gene. Mol Cell Biol 8:2896-2909.
50. Pimentel DR, et al. (2001) Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 89:453-460. (Pubitemid 34132662)